Bain verwendet Cookies, um die Funktionalität und Leistung dieser Website zu verbessern. Weitere Informationen finden Sie in unserer Datenschutzerklärung. Mit Nutzung dieser Website erklären Sie sich mit der Verwendung von Cookies einverstanden.

Bloomberg

Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism

Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism

  • 18. Oktober 2016
  • Min. Lesezeit

Bloomberg

Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism

Large pharmaceutical companies are feeling the pressure from competition with newer pharma companies, particularly in the experimental drug pipelines. These newcomers are gaining footholds in these verticals by building market share in one or two types of tumors or focusing on a technology that can eventually be used more broadly, said Nitin Chaturvedi, a London-based partner with Bain.

“It’s a very credible path to leadership,” Chaturvedi said. “The leadership created through one vertical can be expanded.”